Medtronic Q2 FY25 #EarningsReport Summary | $MDT (+0,2%)

In Q2 FY25, Medtronic exceeded expectations by leveraging innovation and operational efficiency, achieving strong revenue and EPS growth. Guidance for FY25 was raised, underscoring confidence in sustained growth.

📊 Income Statement Highlights (vs. Q2 FY24):

▫️ Net Income: $1.27B vs. $0.91B (+40%)

▫️Total Revenue: $8.40B vs. $7.98B (+5.3%, +5.0% organic)

▫️ GAAP EPS: $0.99 vs. $0.68 (+46%)

▫️ Non-GAAP EPS: $1.26 vs. $1.25 (+1%)

▫️ Operating Profit (GAAP): $1.60B (+19.0%)

▫️ Operating Margin (Non-GAAP): 24.3% (vs. 25.2% in Q2 FY24)

📈 Segment Performance (Organic Growth):

▫️ Cardiovascular: $3.10B (+5.6%)

▫️ Neuroscience: $2.45B (+6.7%)

▫️ Medical Surgical: $2.13B (+0.7%)

▫️ Diabetes: $686M (+11.0%)

💼 Balance Sheet Highlights (vs. April 2024):

▫️ Total Assets: $90.04B (flat)

▫️ Total Liabilities: $41.33B (+4.5%)

▫️ Total Equity: $48.72B (-3.4%)

🔮 Future Outlook:

Medtronic raised FY25 organic revenue growth guidance to 4.75%-5.0% and non-GAAP EPS guidance to $5.44-$5.50. Growth is driven by new product launches and strong pipelines in key franchises like TAVR, Neuromodulation, and Diabetes, despite macroeconomic challenges.